Business Wire

GA-STONEBRANCH

Share
Stonebranch Announces Record-Breaking Growth in 2023, Sets Sights on Future Innovations

Stonebranch, a leading provider of service orchestration and automation solutions, announced another year of significant growth and innovation. Building on the unprecedented success of 2022, Stonebranch has continued to expand its offerings with major product updates and a host of strategic integrations that solidify its position as a leader in the IT automation industry.

New Customer and Partner Relationships Fuel Growth

In 2023, Stonebranch significantly expanded its customer base, welcoming a diverse range of new clients from various sectors, including finance, healthcare, manufacturing, and technology. In addition, new technology, channel, and consulting partnerships enhanced Stonebranch’s capabilities and market reach.

Reflecting on the company's growth, Stonebranch CEO Giuseppe Damiani stated, "2023 was a pivotal year for Stonebranch. Our ability to attract and retain such a diverse clientele speaks volumes about our users' trust and confidence in our solutions. As organizations continue to navigate the complexities of digital transformation, Stonebranch continues to be a provider and partner of choice. It's inspiring to see such a wide array of organizations recognize the value of our solutions, and we’re excited to shape the future of IT automation with them.”

Universal Automation Center Elevates User Experience

Stonebranch introduced substantial enhancements to the Universal Automation Center (UAC) platform in 2023, focusing on elevating the user experience and broadening the scope of automation capabilities for IT Ops, DataOps, MLOps, and CloudOps professionals. Key highlights include the launch of:

  • Observability with OpenTelemetry: UAC 7.5 introduced the OpenTelemetry connector, which makes telemetry data available via the OpenTelemetry standards. This feature collects log, metric, and trace data from UAC and third-party applications integrated with the UAC. Then, it outputs that collected data to application performance management (APM) tools (like Splunk, Dynatrace, and DataDog) and observability/business intelligence tools (like Grafana, Jaeger, and PowerBI).
  • SAP Enhanced View: UAC has always made it easy for IT Ops teams to manage SAP tasks. With the release of UAC 7.5, Stonebranch extended this ease to business users too, by rolling out a new guided interface that’s intuitive for anyone who usually works with SAP ECC or S/4HANA.
  • Jobs-as-Code: Building on UAC’s DevOps capabilities, jobs-as-code enables developers to manage jobs and workflow configuration just like business application code — directly from their integrated development environment (IDE) of choice. Additionally, by integrating UAC with source control repositories like GitHub, GitLab, and Azure DevOps, developers can establish continuous delivery pipelines that offer version control, testing capabilities, and CI/CD best practices.
  • Strategic Integrations for a Connected Ecosystem: 2023 also marked the debut of several pivotal integrations, reinforcing Stonebranch's commitment to foster a more connected and agile IT ecosystem. New integrations include SAP IBP and SAP HANA XSA, DBT, Azure Synapse, SQL OBDC, Fivetran, Databricks, Temenos, Oracle EBS, Azure AZ CLI, Google Cloud Composer, and Red Hat OpenShift. These additions enhance UAC’s ability to seamlessly connect and orchestrate across diverse IT landscapes, driving unparalleled efficiency and innovation.

"Innovation is at the heart of everything we do at Stonebranch,” says Stonebranch CTO Peter Baljet. “Our commitment as a product leader is driven by our customers' rapidly evolving needs as they adopt new IT landscape paradigms. Looking ahead, we aim to enable businesses with the full potential of automation, transforming their operations and setting new levels for agility, observability, and scalability."

Accolades Celebrate Excellence at Stonebranch

Stonebranch is consistently recognized for its innovation, leadership, and workplace culture by prestigious organizations and industry analysts. These accolades highlight Stonebranch's commitment to providing cutting-edge automation solutions and fostering a supportive, dynamic work environment. Some of the notable recognition Stonebranch received in 2023 include:

  • Gartner®: The research and consulting firm recognized Stonebranch in a variety of reports and guides in 2023, such as the Market Guide for Service Orchestration and Automation Platforms (SOAPs), Data and Analytics Essentials: DataOps Report, Hype Cycle for IT Infrastructure and Operations (I&O), and more.
  • EMA: As a Value Leader in the 2023 EMA Radar™ Report for Workload Automation and Orchestration, Stonebranch was recognized as a “top-tier orchestrator capable of automation on-premises and in the cloud.”
  • G2: In its reports for workload automation and managed file transfer, the peer-review platform awarded Stonebranch three Leader badges, a High-Performer badge, and an Easiest Doing Business With badge.
  • Atlanta Journal-Constitution / Energage: Based solely on employee feedback, Stonebranch was recognized as a Metro Atlanta Top Workplace for the second consecutive year.

“These awards and recognitions are not just milestones but also motivation for us at Stonebranch,” noted Damiani. “As we celebrate these achievements, we remain focused on pushing the boundaries of what's possible in IT automation and orchestration.”

About Stonebranch

Stonebranch builds IT orchestration and automation solutions that transform business IT environments from simple IT task automation into sophisticated, real-time business service automation. No matter the degree of automation, the Stonebranch platform is simple, modern, and secure. Using the Stonebranch Universal Automation Platform, enterprises can seamlessly orchestrate workloads and data across technology ecosystems and silos. Headquartered in Atlanta, Georgia, with points of contact and support throughout the Americas, Europe, and Asia, Stonebranch serves some of the world’s largest financial, manufacturing, healthcare, travel, transportation, energy, and technology institutions.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240227593444/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release

Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release

Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye